Lynley Marshall

Lynley Marshall is a consultant in paediatric and adolescent oncology drug development at the Royal Marsden Hospital in London, where she leads the Paediatric and Adolescent Oncology Drug Development team.

After completing her undergraduate training in Johannesburg, South Africa, and south west England, Marshall trained in paediatrics and then as a paediatric oncologist in University of Bristol and Oxford University. She holds a Ph.D. from the Institute of Cancer Research.

Marshall chairs the National Cancer Research Institute Children's cancer and Leukaemia Clinical Studies Novel Agents Subgroup, and is a member of the Innovative Therapies for Children with Cancer (ITCC) European Early Phase Trials Consortium. Provided by Wikipedia
Showing 1 - 3 results of 3 for search 'Lynley Marshall', query time: 0.02s Refine Results
  1. 1
    Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.

    Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. by Dorine A Bax, Suzanne E Little, Nathalie Gaspar, Lara Perryman, Lynley Marshall, Marta Viana-Pereira, Tania A Jones, Richard D Williams, Anita Grigoriadis, Gilles Vassal, Paul Workman, Denise Sheer, Rui M Reis, Andrew D J Pearson, Darren Hargrave, Chris Jones

    Published 2009-01-01
    Get full text
    Article
  2. 2
    An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene

    An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene by Zita Reisz, Rita Pereira, Smitha Nevis, Alan Mackay, Leena Bhaw, Yura Grabovska, Ross Laxton, Valeria Molinari, Anna Burford, Barnaby Clark, Cristina Bleil, Bassel Zebian, Erika Pace, Annette Weiser, Fernando Carceller, Lynley Marshall, Andrew King, Istvan Bodi, Safa Al-Sarraj, Chris Jones, Matthew Clarke

    Published 2025-01-01
    Get full text
    Article
  3. 3
    PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults

    PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults by Nicola Fenwick, Rebekah Weston, Keith Wheatley, Jodie Hodgson, Lynley Marshall, Martin Elliott, Guy Makin, Antony Ng, Bernadette Brennan, Stephen Lowis, Jenny Adamski, John Paul Kilday, Rachel Cox, Mike Gattens, Andrew Moore, Toby Trahair, Milind Ronghe, Martin Campbell, Helen Campbell, Molly W. Williams, Maria Kirby, Natasha Van Eijkelenburg, Jennifer Keely, Ugo Scarpa, Victoria Stavrou, Livingstone Fultang, Sarah Booth, Paul Cheng, Carmela De Santo, Francis Mussai

    Published 2024-01-01
    Get full text
    Article

Search Tools: